1910 Publishes CANDID-CNS(TM), an AI Model That Unlocks Beyond Rule of 5 Chemical Space and Stereochemistry to Predict Blood--Brain Barrier Penetration

BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- 1910, the only AI-native biotech pioneering small and large molecule therapeutics discovery, today announced that its CANDID-CNS (TM) AI model has been ...
EurekAlert!

Insilico Medicine and Tenacia Biotechnology announce research collaboration focused on CNS therapeutics discovery using generative AI

Cambridge, MA, Mar 3, 2025 --- Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, and Tenacia Biotechnology (“Tenacia”), a ...
News Medical

Event guide: The 7th CNS Drug Delivery Summit

The CNS field has been waiting far too long for a true breakthrough in brain-targeted drug delivery. Despite decades of R&D and countless promising candidates, the blood-brain barrier remains the ...
Morningstar

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments ...
Labroots

CNS Delivery in Drug Development and Toxicology: Best Practices and Recent Advances

Central Nervous System (CNS) therapies have significantly progressed in the last decade, propelled by emerging treatment modalities including gene therapies. Neurological indications remain amongst ...
Nasdaq

Polyrizon Ltd. Reports Promising Preclinical Results for CNS Drug Delivery Using Hydrogel-Based Trap & Target Platform

Polyrizon Ltd., a biotechnology company focused on intranasal drug delivery systems, has reported promising preclinical results for its hydrogel-based Trap & Target (T&T) platform, developed in ...